View in EDS PDF Full Text

Uso en vida real de patirómero en pacientes con hiperpotasemia: estudio retrospectivo en la Comunidad Valenciana.

Saved in:
Bibliographic Details
Title: Uso en vida real de patirómero en pacientes con hiperpotasemia: estudio retrospectivo en la Comunidad Valenciana.
Alternate Title: Real-World Use of Patiromer in Patients with Hyperkalaemia: A Retrospective Study from the Valencian Community.
Authors: Moncho-Francés, Francesc1, Gonzales-Candia, Boris1, Perez-Silvestre, José2, Sandin, Miriam3, Sanchez-Perez, Pilar4, Garcia-Maset, Rafael5, Pantoja, Jonay6, Antonio Carbonell-Asins, Juan7, Gimenez-Civera, Elena1, De la Espriella, Rafael8, Jesús Puchades, María1,9, Nuñez, Julio8,9, Luis Górriz, José1,9,10 jlgorriz@gmail.com
Source: Nefrologia. Mar2026, Vol. 46 Issue 3, p1-9. 9p.
Subjects: HYPERKALEMIA, DRUGS, RETROSPECTIVE studies, MINERALOCORTICOID receptors, CHRONIC kidney failure, ADVERSE health care events, RENIN-angiotensin system
Geographic Terms: VALENCIA (Spain)
Abstract (English): Background and objective: Hyperkalaemia is common in patients with chronic kidney disease (CKD) treated with renin-angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs). Although new potassium binders have demonstrated efficacy in clinical trials, evidence from realworld clinical practice remains limited. Materials and methods: We present a retrospective, observational, multicentre, non-interventional study aimed at evaluating the use of patiromer in patients with hyperkalaemia under routine clinical conditions in the Valencian Community. Patients who received patiromer for at least 3 months due to hyperkalaemia were included. The primary objective was to assess the evolution of serum potassium at 1, 3, 6, and 12 months after initiation of treatment. Secondary objectives included describing baseline patient characteristics, changes in RAASi and MRA therapy, and patiromer-related adverse events. Results: A total of 59 patients were included. The baseline serum potassium level was 5.72 mmol/L, showing significant reductions at 1, 3, 6, and 12 months (5.02, 5.17, 5.11, and 5.01 mmol/L, respectively; all p < 0.001). Patiromer treatment enabled continuation of RAASi in 94.9% of patients and MRAs in 98.3%. The most frequent adverse events were gastrointestinal. Patiromer was discontinued in 8 patients (13.5%), with adverse effects accounting for half of these cases. Conclusions: Our study provides real-world evidence on the effectiveness, safety, and RAASi/MRA maintenance potential of patiromer in patients with CKD and hyperkalaemia under routine care. In this setting, patiromer proved effective and well tolerated for managing hyperkalaemia and preserving RAASi/MRA therapy. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Introduccion y objetivos: La hiperpotasemia (HK) es frecuente en pacientes con enfermedad renal crónica (ERC) tratados con inhibidores del sistema renina-angiotensina-aldosterona (iSRAA) y antagonistas del receptor de mineralocorticoides (ARM). Aunque los nuevos quelantes han mostrado eficacia en ensayos clínicos, falta evidencia en práctica clínica real. Materiales y métodos: Presentamos un estudio retrospectivo observacional, multicéntrico, no intervencionista con el objetivo de evaluar el uso de patirómero en pacientes con HK en condiciones de práctica clínica habitual en la Comunidad Valenciana. Se incluyeron pacientes que habían recibido patirómero al menos tres meses por haber presentado HK. El objetivo primario del estudio fue evaluar la evolución del potasio sérico a los meses 1, 3, 6 y 12 del inicio del tratamiento. Los objetivos secundarios fueron definir las características basales de los pacientes, las modificaciones en el tratamiento con iSRAA y ARM y los efectos secundarios relacionados con patirómero. Resultados: Se incluyeron 59 pacientes. El valor inicial de potasio sérico fue de 5,72 mmol/L, mostrando descensos significativos al mes, 3, 6 y 12 meses (5,02 mmol/L, 5,17 mmol/L, 5,11 mmol/L y 5,01 mmol/L, respectivamente. Todos p < 0,001). El tratamiento con patirómero permitiómantener los iSRAA en el 94,9% de los pacientes y los ARM en el 98,3%. Los efectos adversos más frecuentes fueron de carácter gastrointestinal. El patirómero fue suspendido en ocho pacientes (13,5%), siendo la causa los efectos adversos solo en la mitad de ellos. Conclusiones: Nuestro estudio proporciona evidencia real sobre la eficacia, seguridad y capacidad de mantenimiento de iSRAA y ARM de patirómero en pacientes con ERC e HK tratados en condiciones de práctica clínica habitual. [ABSTRACT FROM AUTHOR]
Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
Description
Abstract:Background and objective: Hyperkalaemia is common in patients with chronic kidney disease (CKD) treated with renin-angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs). Although new potassium binders have demonstrated efficacy in clinical trials, evidence from realworld clinical practice remains limited. Materials and methods: We present a retrospective, observational, multicentre, non-interventional study aimed at evaluating the use of patiromer in patients with hyperkalaemia under routine clinical conditions in the Valencian Community. Patients who received patiromer for at least 3 months due to hyperkalaemia were included. The primary objective was to assess the evolution of serum potassium at 1, 3, 6, and 12 months after initiation of treatment. Secondary objectives included describing baseline patient characteristics, changes in RAASi and MRA therapy, and patiromer-related adverse events. Results: A total of 59 patients were included. The baseline serum potassium level was 5.72 mmol/L, showing significant reductions at 1, 3, 6, and 12 months (5.02, 5.17, 5.11, and 5.01 mmol/L, respectively; all p < 0.001). Patiromer treatment enabled continuation of RAASi in 94.9% of patients and MRAs in 98.3%. The most frequent adverse events were gastrointestinal. Patiromer was discontinued in 8 patients (13.5%), with adverse effects accounting for half of these cases. Conclusions: Our study provides real-world evidence on the effectiveness, safety, and RAASi/MRA maintenance potential of patiromer in patients with CKD and hyperkalaemia under routine care. In this setting, patiromer proved effective and well tolerated for managing hyperkalaemia and preserving RAASi/MRA therapy. [ABSTRACT FROM AUTHOR]
ISSN:02116995
DOI:10.1016/j.nefro.2025.501454